|
|
Haemonetics Corporation (NYSE: HAE) |
|
Price: $57.5600
$-0.74 
-1.269%
|
| Day's High:
| $57.56
| Week Perf:
| -2.89 %
|
| Day's Low: |
$ 56.64 |
30 Day Perf: |
-11.01 % |
| Volume (M): |
107 |
52 Wk High: |
$ 97.97 |
| Volume (M$): |
$ 6,132 |
52 Wk Avg: |
$78.17 |
| Open: |
$56.72 |
52 Wk Low: |
$55.30 |
|
|
| Market Capitalization (Millions $) |
2,915 |
| Shares
Outstanding (Millions) |
51 |
| Employees |
4,209 |
| Revenues (TTM) (Millions $) |
1,373 |
| Net Income (TTM) (Millions $) |
130 |
| Cash Flow (TTM) (Millions $) |
127 |
| Capital Exp. (TTM) (Millions $) |
33 |
Haemonetics Corporation
Haemonetics Corporation is a U.S. based company that specializes in providing innovative blood management solutions to healthcare facilities and blood donation centers across the globe. The company was founded in 1971 and is headquartered in Braintree, Massachusetts. Haemonetics Corporation has a market cap of roughly $4.4 billion and trades on the New York Stock Exchange under the ticker symbol HAE.
The company has a wide range of products and services including blood collection and processing equipment, blood component extraction and storage systems, and software platforms for blood management. Haemonetics Corporation's major products include:
1. Blood Collection Devices and Systems - Haemonetics Corporation produces a variety of different products designed to collect blood safely and efficiently. These devices include manual and automated collection instruments, needles and tubing, and blood bags.
2. Blood Component Separation and Storage Systems - The company produces systems that separate blood into its various components such as red blood cells, plasma, and platelets. These components can then be stored separately and used for various medical procedures as needed.
3. Blood Management Software - In order to assist healthcare facilities with managing their blood inventory and ensuring patient safety, Haemonetics Corporation offers a range of software applications. These applications allow healthcare professionals to track blood usage, monitor inventory levels, and analyze patient transfusion trends.
Haemonetics Corporation serves a diverse range of clients, including hospitals, blood banks, and surgery centers. The company's products and services are used in a variety of medical procedures, including surgeries, transfusions, and emergency care.
The company has a global presence, with operations in over 50 countries. Haemonetics Corporation employs approximately 3,200 people worldwide and has manufacturing facilities in the U.S., Mexico, and Switzerland.
In recent years, Haemonetics Corporation has made significant investments in research and development, with a focus on developing new products that enhance blood management practices and improve patient outcomes. The company has also been actively acquiring other firms in the industry, further expanding its product portfolio and market share.
Overall, Haemonetics Corporation is a highly reputable and innovative company that is dedicated to providing the highest quality blood management solutions to healthcare facilities worldwide.
Company Address: 125 Summer Street Boston, 2110 MA
Company Phone Number: 848-7100 Stock Exchange / Ticker: NYSE HAE
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Haemonetics Corporation
Haemonetics Corporation, a leading Medical Equipment & Supplies company, recently announced its financial results for the most recent fiscal period. While the company experienced a double-digit increase in revenue, its net profit per share dropped significantly, leading to concerns about its financial performance.
In the most recent fiscal period, Haemonetics Corporation reported a 12.664% increase in revenue, reaching $343.91 million. This growth in revenue is noteworthy, especially when compared to the overall top-line growth of 7.27% experienced by the Medical Equipment & Supplies industry during the same period. This suggests that Haemonetics Corporation performed favorably compared to its industry peers.
|
| Haemonetics Corporation
The Medical Equipment & Supplies company, Haemonetics Corporation, faced a decline in earnings per share (EPS) in the third quarter of the 2024 earnings season despite experiencing revenue growth. The bottom-line decreased by 4.69% to $0.61 per share, while revenue saw a significant increase of 10.226% to $335.87 million compared to the same period in the previous year.
In comparison to the preceding financial reporting period, the bottom-line grew by 27.08% from $0.48 per share, and the revenue increased by 5.782% from $317.51 million. However, in the October to December 30, 2023 fiscal time-frame, the bottom-line dropped by 5.17% to $31.241 million from $32.944 million in the corresponding period a year before.
|
| Haemonetics Corporation
The Medical Equipment & Supplies company, Haemonetics Corporation, recently released their financial results for the second quarter of 2024. While the report showed conflicting results, the company managed to outperform its sector peers on the business side.
In terms of revenue, Haemonetics Corporation experienced a growth of 6.95% compared to the same period last year, with revenue totaling $317.51 million. This was a significant increase from $296.88 million in the prior year reporting period. However, the company's income fell by 25% to $0.48 per share from $0.64 per share in the previous year. Despite this decline in income, Haemonetics Corporation remained ahead of its sector peers, who reported a revenue rise of only 2.66% during the same period.
|
| Haemonetics Corporation
Date: September 5, 2023
Haemonetics Corporation, a leading player in the Medical Equipment & Supplies industry, has showcased robust financial results for the period between May and July 2023. The company's impressive revenue growth, soaring income per share, and improved profitability have caught the attention of Wall Street investors.
During this period, Haemonetics Corporation's revenue reached an outstanding $311.27 million, marking a remarkable year-on-year increase of 19.139%. In addition, the company's revenue surged quarter on quarter by 1.971%. Such commendable growth outpaced most of its peers in the Medical Equipment & Supplies sector. According to recent reports, almost two-thirds of businesses in the industry experienced only a 3.90% increase in revenue from the first quarter of 2023.
|
| Haemonetics Corporation
Investors in Haemonetics Corporation can expect solid growth and increased earnings based on the company's fiscal fourth quarter 2023 financial results. The medical equipment and supplies company reported an impressive 71.13% increase in income per share to $0.77 compared to the previous year, while revenues grew by 31.706% to $342.13 million.
The company's net earnings also saw a healthy increase of 69.37% to $39.348 million. Although operating margin fell to 13.54%, the net margin actually improved to 11.5%. Operating earnings, however, only improved by 29.97% to $46.336 million.
|
| Per Share |
Current |
| Earnings (TTM) |
2.53 $ |
| Revenues (TTM) |
27.11 $
|
| Cash Flow (TTM) |
2.51 $ |
| Cash |
6.34 $
|
| Book Value |
17.91 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
2.53 $
|
| Revenues (TTM) |
27.11 $ |
| Cash Flow (TTM) |
2.51 $ |
| Cash |
6.34 $
|
| Book Value |
17.91 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| United States |
|
 74.14 % |
of total Revenue |
| Japan |
|
4.65 % |
of total Revenue |
| Europe |
|
12.71 % |
of total Revenue |
| Rest of Asia |
|
7.37 % |
of total Revenue |
| Other |
|
1.42 % |
of total Revenue |
| Plasma |
|
38.67 % |
of total Revenue |
| Plasma Plasma |
|
38.62 % |
of total Revenue |
| Blood Center |
|
20.35 % |
of total Revenue |
| Blood Center Blood Center |
|
20.24 % |
of total Revenue |
| Apheresis Blood Center |
|
15.94 % |
of total Revenue |
| Whole Blood Blood Center |
|
4.3 % |
of total Revenue |
| Hospital |
|
41.5 % |
of total Revenue |
| Hospital Hospital |
|
41.43 % |
of total Revenue |
| Vascular Closure Hosptial Hospital |
|
18.2 % |
of total Revenue |
| Hemostasis Management Hospital Hospital |
|
23.23 % |
of total Revenue |
|
|
3.77% 